Myriad RBM DiscoveryMAP® Technology Identifies Novel Biomarkers that May Predict Increased Risk of Cardiovascular Events in Patients with Diabetes
Protein Biomarkers May Accelerate the Future of Personalized Medicine for CV Disease
SALT LAKE CITY, Utah, Nov. 16, 2015 – Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that its DiscoveryMAP® platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, according to a study published by the journal Circulation.
Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa™ Platform
SALT LAKE CITY, Utah, March 5, 2015 – Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., (NASDAQ: MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis
SALT LAKE CITY, Utah, Jan. 20, 2015 – Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur.
Institut Pasteur and Myriad RBM Publish Initial Results from Landmark Study of Immune Response
PARIS, France and SALT LAKE CITY, Utah, March 20, 2014- Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response…
DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration Collaboration Will Focus on Development of Novel Diagnostic Tests for Dialysis Patients
SALT LAKE CITY, Utah, June 17, 2013- DaVita Labs, a unit of DaVita HealthCare Partners Inc. (NYSE: DVA) and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics (NASDAQ: MYGN) announced today a research collaboration to conduct protein biomarker discovery research with the goal of developing and commercializing diagnostic tests that could benefit in the treatment of dialysis patients.
Myriad Announces Diabetes Collaboration with Sanofi Salt Lake City, December 10, 2012
Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBM will perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the world’s longest and largest randomized clinical trial in pre- and early diabetes. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI.
Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research HERCULES, CA and AUSTIN, TX July 24, 2012
Bio Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc. (NASDAQ: MYGN), and a leading multiplex biomarker testing company, today announced that they have partnered to develop and distribute high-quality immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex 3D, and Bio-Plex® MAGPIX™ instruments.
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0 Salt Lake City, UT (PRWEB) May 09, 2012
Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. OncologyMAP® v. 2.0 is a comprehensive, cost-effective testing service that builds on the success of the original OncologyMAP® service by increasing the scope and diversity of biomarker analysis for drug re-tasking, indication expansion, and patient stratification studies and provides researchers with the ability to accelerate the pace of discovery, validation, and translation of cancer biomarkers into clinically useful tests.
The Spinal Muscular Atrophy Foundation Announces a Biomarker Panel to Guide SMA Therapeutic Development NEW YORK, NY – April 3, 2012
The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM’s Multi-Analyte Profiling (MAP) technology platform. The SMA-MAP panel is designed to evaluate the severity of SMA and disease progression and can be used to assess drug efficacy and shorten the duration of clinical trials for SMA therapeutics.
Myriad Genetics Completes Acquisition of Rules-Based Medicine SALT LAKE CITY and AUSTIN- June 1, 2011
Myriad Genetics Inc. (NASDAQ: MYGN) today announced that it has completed the previously announced acquisition of Rules-Based Medicine (RBM) for approximately $80 million in cash. Rules-Based Medicine is a leader in the discovery of novel biomarkers for its pharmaceutical and biotechnology partners utilizing its proprietary multiplex immunoassay technology. RBM’s protein detection platform provides pharmaceutical companies with critical information that can accelerate drug development research and improve clinical trial outcomes.
Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche Milestone Demonstrates Effectiveness of RBM’s Strategic Biomarker Services
AUSTIN, Texas, May 25, 2011 /PRNewswire/ — Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova’s biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.
Rules-Based Medicine Acquires Intellectual Property Assets of Satoris, Inc. Expansion of IP portfolio to support development and commercialization of novel tests for neurodegenerative diseases.
AUSTIN, Texas, May 17, 2011 /PRNewswire/ — Rules-Based Medicine (RBM), a global leader in biomarker testing services, today announced the acquisition of intellectual property assets from Satoris, Inc. The portfolio is based on extensive research to discover biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease, and other conditions that affect the central nervous system.
Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research RBM’s TruCulture® sample collection system will be an integral part of study.
AUSTIN, Texas, May 12, 2011 /PRNewswire/ — Rules-Based Medicine, Inc. a leading provider of multiplexed protein biomarker services will be a collaborator on the Institut Pasteur research project Milieu Interieur (the environment within), funded through a LabEx grant from the French government. The project will rely on RBM’s TruCulture® R an innovative in vitro model that preserves physiological cellular interactions, to more accurately describe the complexities of the human immune system.
Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine Acquisition Expands Myriad’s Leadership Position in Companion Diagnostics
SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) — Myriad Genetics Inc. (Nasdaq:MYGN) today announced that it has entered into a definitive merger agreement to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas for $80 million in cash. The deal expands Myriad’s research portfolio into new disease states, including psychiatric disorders, infectious diseases and inflammatory diseases, and adds eight new molecular diagnostic product candidates to Myriad’s already strong pipeline. RBM’s history of strategic alliances with over 20 major pharmaceutical and biotechnology companies, coupled with Myriad’s position in PARP inhibitors and PI3K inhibitors, creates a leading franchise in companion diagnostics. Furthermore, the RBM acquisition provides Myriad with access to patient cohorts for new diagnostic development and is expected to enhance Myriad’s industry-leading DNA and RNA technologies with unparalleled strength in protein discovery and analysis.
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
Panel of 101 quantitative biomarker tests selected in partnership with the National Cancer Institute
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development Panel of 101 quantitative biomarker tests selected in partnership with the National Cancer Institute
AUSTIN, Texas, March 24, 2011 /PRNewswire/ — Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer. OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service.
SMA Foundation and Rules-Based Medicine Collaborate on Biomarker Panels to Guide SMA Therapeutic Development
NEW YORK, NY AND AUSTIN, TX — January 19, 2011 — The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine, Inc. (RBM) announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) technology platform. In this collaboration, RBM will discover and also confirm plasma protein biomarker candidates previously identified from the multicenter Biomarkers for SMA (BforSMA) clinical study sponsored by the SMA Foundation and conducted by BG Medicine. The identification of such biomarkers may help to assess drug efficacy and shorten the duration of clinical trials of SMA therapies.
Rules-Based Medicine, Inc. Awarded Funding from the Cancer Prevention and Research Institute of Texas
Multimillion Dollar Award to Expand OncologyMAP Program for Novel Cancer Tests
AUSTIN, TX (June 23, 2010) — Rules-Based Medicine, Inc. (RBM) today announced the Cancer Prevention and Research Institute of Texas (CPRIT) has granted it a Company Commercialization Award to expand and enhance the OncologyMAP program for discovery and development of novel diagnostic and prognostic cancer tests. The award of approximately $3 million will fund research and development to more than double the number of cancer-associated biomarker assays in RBM’s new OncologyMAP product.
Rules-Based Medicine and Psynova Neurotech Announce Companion Diagnostic Collaboration with Roche
Utilizing Psynova’s schizophrenia biomarker portfolio and RBM’s DiscoveryMAP technology
AUSTIN, TX (December 2, 2009) — Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.
Rules-Based Medicine Forms Biomarker Alliance with Covance Inc.
Deal Expands Access to Clinical Trials Market for Multiplexed Biomarker Services
SAN DIEGO, CA — November 18, 2009 — Rules-Based Medicine, Inc. (RBM) today announced it has entered into a biomarker alliance and services agreement with Covance Inc. (NYSE:CVD) that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services. Financial terms of the agreement were not disclosed.
Rules-Based Medicine Introduces CardiovascularMAP Multiplex Biomarker Panel To Aid CVD Development
Austin, Texas, October 28, 2009 — Rules-Based Medicine (RBM), a leading multiplexed biomarker testing laboratory, today announced the launch of CardiovascularMAP, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease (CVD). Designed in collaboration with leading pharmaceutical and biotechnology research groups, the 50-biomarker panel combines biomarkers most commonly associated with CVD progression with additional markers to identify new patterns of disease, resulting in a potentially powerful new tool for researchers.
Rules-Based Medicine, Inc. and Psynova Neurotech Ltd. Identify Diagnostic Biomarker Panel for Schizophrenia
Austin, Texas and Cambridge, England, October 20, 2009 — Rules-Based Medicine, Inc. (RBM) and Psynova Neurotech Ltd. (Psynova) today announced the discovery and characterization of a combination of protein biomarkers demonstrating utility as an adjunctive aid in the differential diagnosis of schizophrenia. As a result of this clinical milestone, RBM has made additional investments in Psynova, and now has a controlling interest in the company.
Rules-Based Medicine, Inc. Launches DiscoveryMAP Service for Drug and Diagnostic Development
Austin, Texas, June 17, 2009 — Rules-Based Medicine, Incorporated (RBM), the world’s leading multiplexed biomarker testing laboratory, today announced the availability of the most comprehensive collection of quantitative immunoassays for use in advancing safety, efficacy and efficiency in drug and diagnostic development. The new service, DiscoveryMAP v 1.0, offers customers dynamic coverage of most physiologically relevant pathways, providing biological information and leads for further study. This unique and comprehensive offering increases the odds of identifying new protein biomarker patterns in almost any drug development or diagnostic discovery project.
Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
Complements the RBM Rat Kidney Panel developed in conjunction with the Critical Path Initiative
AUSTIN (January 15, 2009) — Rules-Based Medicine, Inc. (RBM), the world’s leading multiplexed biomarker testing laboratory, today announced the launch of its Human Kidney Multi-Analyte Profile (MAP), a cost-effective biomarker testing service designed to aid pharmaceutical and biotechnology companies in their efforts to improve drug development through better understanding of drug toxicity. The Human Kidney MAP will be used in clinical trials to reveal early signs and locations of drug-induced kidney damage, known as renal toxicity or nephrotoxicity, thereby guiding important decisions on lead compounds and dosage.
National Cancer Institute Awards Small Business Innovation Research Contract To Rules-Based Medicine, Inc.
RBM to Expand Research Collaboration with Correlogic Systems, Inc. Aimed at Multiplex Diagnostic Tests for Ovarian Cancer
AUSTIN, TX (December 18, 2008) — Rules-Based Medicine, Inc. (RBM) and Correlogic Systems, Inc. today announced the award of a National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to RBM that will further research on ovarian cancer diagnostic tests. The contract was awarded through a peer-reviewed competitive process to develop biomarker panels for the early detection of cancer and includes a Phase I “Fast-Track” component and Phase II option, together totaling $1.15 million.
Race for mental illness test on
Rules-Based Medicine working on fast, accurate blood diagnosis tool.
By Lilly Rockwell
AUSTIN, TX (August 11, 2008) — Ever since the recent discovery that schizophrenia can be diagnosed using blood analyses instead of traditional psychiatric methods, companies have rushed to find a way to bring such a test to market.
Rules-Based Medicine Commercializes New Toxicity Biomarker Panel in Conjunction with FDA, EMEA, C-Path and PSTC
For use in pre-clinical trials to evaluate early renal toxicity, new Rat Kidney MAP will aid in faster development of safer drugs
AUSTIN, TX (June 30, 2008) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has commercialized a new biomarker panel to aid pharmaceutical and biotech companies evaluate renal toxicity in rats for pre-clinical drug trials. RBM’s Rat Kidney MAP (multi-analyte profile) measures key biomarkers found in urine that can provide additional information about drug-induced damage to kidney cells, known as renal toxicity or nephrotoxicity.
Rules-Based Medicine and Psynova Neurotech to Co-Develop Blood Test for Diagnosis of Schizophrenia
Partnership gives RBM exclusive rights to market and sell diagnostic test worldwide
AUSTIN, TX (June 11, 2008) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, announced today that it is partnering with Psynova Neurotech to co-develop and commercialize a blood test for the diagnosis of schizophrenia. RBM and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia. Under the terms of the agreement, the companies will collaborate on the validation, regulatory approval and manufacture of a diagnostic blood test for schizophrenia that will be sold worldwide exclusively by RBM.
Rules-Based Medicine Partners with EMD to Develop and Distribute Multi-Analyte Kits
Pharmaceutical, biotechnology and academic labs to gain access to the industry’s largest catalog of quantitative protein multiplex assays
AUSTIN, TX (December 10, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it is partnering with the Novagen brand of EMD Chemicals Inc. (EMD), a subsidiary of Merck KGaA (Merck) of Germany, to develop and distribute high-quality immunoassay products on the Luminex xMAP platform. Under the terms of the agreement, RBM is granting EMD/Merck exclusive distribution rights to the largest catalog of quantitative protein multiplex assays currently available.
Rules-Based Medicine Raises $25 Million in Series A Funding
Equity Group Investments leads round, joined by Cross Creek Capital and Stephens Capital Partners; Matt Zell named to Board of Directors
AUSTIN, TX (October 15, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, announced today that it has raised $25 million in private financing. Equity Group Investments LLC (EGI), an investment fund founded by Sam Zell, led the Series A investment round. EGI is joined by Cross Creek Capital, the private equity affiliate of Wasatch Advisors, Inc. and Stephens Capital Partners. The financing will provide growth capital, debt repayment, and funding for acquisitions and investments to discover and validate biomarkers for medical diagnostics. In conjunction with the funding, RBM also announced that Matt Zell, managing director of EGI, has joined its Board of Directors.
Rules-Based Medicine Awarded $849,000 Grant by the National Institutes of Health
AUSTIN, Texas—(BUSINESS WIRE)—November 15, 2007—Rules-Based Medicine, Inc. (RBM) announced today that the National Institutes of Health has awarded RBM a “Fast-Track” grant for the development of a diagnostic test for neonatal sepsis. The grant, entitled “Biomarker Profiles for Early Diagnosis of Sepsis in Neonates,” utilizes RBM’ s HumanMAP platform to characterize and validate a pattern of biomarkers that can detect early signs of infection in newborns. This project will be performed in collaboration with the University of New Mexico (UNM) in Albuquerque.
National Cancer Institute Awards $1.1 Million SBIR Contract to Rules-Based Medicine, Inc.
Goals of Funding are Earlier Detection and Better Characterization of Cancer
AUSTIN (October 10, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that the National Cancer Institute (NCI) has awarded the company a Phase I/Phase II “Fast-Track” Small Business Innovation Research (SBIR) Contract valued at $1,126,627. The contract will fund the development of 50 new quantitative, multiplexed immunoassays for cancer-related proteins to be added to the automated RBM Human Multi-Analyte Profile (HumanMAP) platform. With the addition of these tests, RBM’s HumanMAP will be expanded to more than 100 quantitative immunoassays for cancer biomarkers (as part of an existing panel of nearly 300 immunoassays) available for fast, sensitive, reproducible and cost-effective use by the worldwide community of cancer researchers.
Rules-Based Medicine Merges with EDI GmbH
Acquisition to benefit pharmaceutical, biotechnology and consumer products industries with comprehensive ex vivo biomarker testing platforms to aid pre-clinical and clinical research
AUSTIN, TX (October 9, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has acquired Experimentelle and Diagnostische Immunologie, GmbH, (EDI) in Reutlingen, Germany, an innovative developer of human organotypic (HOT) cell culture test systems. This transaction leverages the strong synergies between EDI’s HOT cultures and RBM’s Multi-Analyte Profiling (MAP) biomarker testing services. Researchers in the pharmaceutical, biotechnology and consumer products industries will benefit from these comprehensive ex vivo biomarker testing platforms, which will help bring safer products to market faster and at a lower cost. Terms of the agreement were not disclosed.
Rules-Based Medicine Awarded Phase II STTR Contract by U.S. Department of Defense
Austin, Texas, February, 2007 — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has been awarded a Phase II Small Business Technology Transfer (STTR) grant by the United States Department of Defense entitled “Rapid Assessment of Individual Soldier Operational Readiness.”
Changing Game Plan for Protein Profiling
January 1, 2007 — Genetic Engineering News & Biotechnology. Volume 27, Number 1. “The Changing Game Plan for Protein Profiling”. Integrated approaches are becoming the standard paradigm for proteomic studies. The “Multiplex Protein Biomarker Profiling” subsection highlights RBM’s capabilities including analyte menu expansion strategy and technology advantages.
Rules-Based Medicine and Multiplex Biosciences Merge
Merger extends R&D capabilities and product expertise; expands customer base
AUSTIN (November 15, 2006) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has merged with Lake Placid, New York-based Multiplex Biosciences, Inc. to extend its research and development capability in multiplexed assay product development and expand its customer base.